Expanding Access to Medication Abortions

JAMA. 2022 Jan 11;327(2):112-114. doi: 10.1001/jama.2021.23357.
No abstract available

Publication types

  • News

MeSH terms

  • Abortifacient Agents, Nonsteroidal* / administration & dosage
  • Abortifacient Agents, Steroidal* / administration & dosage
  • Abortifacient Agents, Steroidal* / supply & distribution
  • Abortion, Legal / legislation & jurisprudence
  • Abortion, Legal / methods
  • Abortion, Legal / statistics & numerical data*
  • Adolescent
  • Adult
  • COVID-19 / epidemiology
  • Criminal Law
  • Drug Prescriptions
  • Female
  • Humans
  • Middle Aged
  • Mifepristone* / administration & dosage
  • Mifepristone* / supply & distribution
  • Misoprostol* / administration & dosage
  • Pandemics
  • Pharmaceutical Services, Online
  • Pharmacists
  • Pregnancy
  • Pregnancy Trimester, First
  • Risk Evaluation and Mitigation / legislation & jurisprudence
  • Self Administration / statistics & numerical data
  • Self Medication / statistics & numerical data*
  • Self-Management / methods
  • Self-Management / statistics & numerical data
  • Telemedicine / organization & administration
  • United States
  • United States Food and Drug Administration
  • Young Adult

Substances

  • Abortifacient Agents, Nonsteroidal
  • Abortifacient Agents, Steroidal
  • Misoprostol
  • Mifepristone